Table 2 Demographic data of patients in the training and validation cohorts

Age (Years, Mean ± SD)

51.57 ± 14.09

47.65 ± 14.90

0.178^a

56.27 ± 20.46

48.15 ± 14.68

0.165^a

0.660^a

Sex, n (%)

0.7053^b*

0.246^b

0.392^b

 Male

32(0.53)

25(0.49)

7(0.32)

14(0.52)

 Female

28(0.47)

26(0.51)

15(0.68)

13(0.48)

Tumor Location

0.570^b

0.567^b

0.864^b

 Limb

28(0.47)

27(0.53)

9(0.41)

14(0.52)

 Body

32(0.53)

24(0.47)

13(0.59)

13(0.48)

Peritumoral Hyperintensity

< 0.0001^b*

0.001^b*

> 0.999^b

 No

38(0.63)

9(0.18)

15(0.68)

5(0.19)

 yes

22(0.37)

42(0.82)

7(0.32)

22(0.81)

Size

0.306^b*

0.388^b

0.111^b

 < 5 cm

44(0.73)

32(0.82)

14(0.64)

13(0.48)

 ≥ 5 cm

16(0.27)

19(0.18)

8(0.36)

14(0.52)

Margin

0.329^b

0.3931^b

0.224^b

 Well-defined

20(0.33)

22(0.43)

9(0.41)

15(0.56)

 Poorly-defined

40(0.67)

29(0.57)

13(0.59)

12(0.44)

Signal Intensity

> 0.999^b

0.260^b

0.0009^b

 Homogeneous

42(0.70)

35(0.69)

11(0.50)

9(0.33)

 Heterogeneous

18(0.30)

16(0.31)

11(0.50)

18(0.67)